Ginkgo biloba / MAOB Cancer Research Results

Gb, Ginkgo biloba: Click to Expand ⟱
Features:
Ginkgo biloba from an ancient tree.
Ginkgo biloba leaf extracts (commonly standardized as EGb 761, ~24% flavonol glycosides and ~6% terpene lactones) are best known for antioxidant, anti-inflammatory, platelet-activating factor (PAF) antagonism, and neurovascular effects. In preclinical cancer models, Ginkgo constituents have been associated with modulation of NF-κB, Nrf2, MAPK, and PI3K/AKT pathways, along with effects on cell cycle, apoptosis, and angiogenesis. Clinical oncology evidence is limited and heterogeneous. Important safety considerations include antiplatelet effects (bleeding risk) and CYP/P-gp interactions (product- and dose-dependent).

-Ginkgo can inhibit platelet aggregation

-Scavenges free radicals; reduces oxidative stress in neuronal cells -Suppresses pro-inflammatory cytokines (e.g., TNF-α, IL-1β).
-Enhances microcirculation and oxygen delivery to brain tissues.
-Reduces Aβ plaque formation and associated neurotoxicity.
-May improve memory, attention, and processing speed in early-stage AD.


Rank Pathway / Axis Cancer / Tumor Context Normal Tissue Context TSF Primary Effect Notes / Interpretation
1 Antioxidant systems (Nrf2/ARE; SOD, GSH) Stress adaptation modulation (context-dependent) Nrf2 ↑; antioxidant enzymes ↑; oxidative injury ↓ R, G Redox buffering Flavonol glycosides commonly activate antioxidant defenses; direction in tumors is model-dependent.
2 NF-κB inflammatory transcription NF-κB ↓; cytokines/COX-2 ↓ (reported) Inflammation tone ↓ R, G Anti-inflammatory signaling Preclinical studies report NF-κB modulation; strength varies by constituent and dose.
3 PAF receptor antagonism (ginkgolides) Pro-tumor inflammatory signaling ↓ (context) Platelet activation ↓; microcirculation effects P, R Lipid mediator antagonism Ginkgolides are PAF antagonists; clinically relevant for antiplatelet/vascular effects.
4 PI3K → AKT (± mTOR) survival axis PI3K/AKT modulation (reported; model-dependent) ↔ R, G Growth/survival modulation Observed in some tumor models; best described as reported/context-dependent.
5 MAPK re-wiring (ERK / JNK / p38) MAPK modulation (context-dependent) ↔ P, R, G Stress/mitogenic signaling adjustment Directions vary by extract composition and cell type.
6 Cell-cycle control (Cyclins/CDKs) Cell-cycle arrest ↑ (reported) ↔ G Cytostasis Reported in vitro; typically downstream of signaling changes.
7 Intrinsic apoptosis (mitochondrial/caspase linked) Apoptosis ↑ (reported) ↔ G Cell death execution Seen in selected cancer cell lines; not a universal cytotoxin signature.
8 Angiogenesis signaling (VEGF & related) Angiogenic outputs ↓ (reported) ↔ G Anti-angiogenic phenotype Phenotype-level outcomes in some models; strength varies.
9 Drug metabolism / transport (CYPs, P-gp) Potential interaction with chemo agents (context) CYP/P-gp modulation (product- and dose-dependent) R, G Interaction constraint Reports of CYP (e.g., CYP2C19/3A4) and P-gp modulation are mixed; interaction risk depends on extract and dose.
10 Safety constraint (antiplatelet / bleeding risk) — Platelet aggregation ↓; bleeding risk ↑ (context) — Clinical risk management PAF antagonism and antiplatelet effects warrant caution with anticoagulants/antiplatelets and perioperatively.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (rapid receptor/mediator interactions; early redox shifts)
  • R: 30 min–3 hr (acute signaling and transcription changes)
  • G: >3 hr (gene-regulatory adaptation and phenotype outcomes)
Ginkgo biloba — Alzheimer’s Disease (AD) Mechanism Table
Rank Pathway / Axis AD / Neural Context TSF Primary Effect Notes / Interpretation
1 Oxidative stress reduction (Nrf2/ARE; SOD, GSH) Oxidative injury ↓; lipid peroxidation ↓ R, G Neuroprotection via redox buffering Flavonol glycosides enhance endogenous antioxidant defenses and reduce oxidative stress, a core driver in AD pathology.
2 Mitochondrial protection ATP production stabilization; mitochondrial membrane integrity ↑ P, R Energy support EGb 761 has been reported to protect mitochondrial function and reduce ROS generation in neuronal models.
3 Neuroinflammation (NF-κB; microglial activation) Microglial activation ↓; pro-inflammatory cytokines ↓ R, G Anti-inflammatory neuroprotection Reduction of neuroinflammatory signaling may contribute to slowed neurodegenerative processes.
4 Platelet-activating factor (PAF) antagonism Improved cerebral microcirculation; reduced inflammatory mediator activity P Vascular support Ginkgolides act as PAF antagonists; improved cerebral blood flow may support cognition in vascular/mixed dementia.
5 β-amyloid aggregation modulation Aβ aggregation ↓ (reported in vitro) G Protein aggregation modulation Preclinical studies suggest interference with Aβ toxicity and aggregation; clinical relevance remains uncertain.
6 Synaptic plasticity / neurotransmission Cholinergic tone modulation (reported); synaptic resilience ↑ G Cognitive support Some evidence suggests improved synaptic function and neurotransmission in aging models.
7 Apoptosis suppression (neuronal survival) Pro-apoptotic signaling ↓ (reported) G Neuronal preservation Reduction of caspase activation and mitochondrial apoptotic signaling has been reported in neuronal injury models.
8 Clinical cognitive outcomes Modest cognitive benefit in mild-to-moderate dementia (mixed results) — Symptom-level effect Some randomized trials suggest small improvements in cognition or activities of daily living; others show limited effect. Benefit appears modest.
9 Safety constraint (antiplatelet effect) Bleeding risk ↑ in susceptible patients — Clinical risk management PAF antagonism and platelet aggregation inhibition require caution with anticoagulants and perioperative settings.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (rapid receptor and mitochondrial interactions)
  • R: 30 min–3 hr (acute inflammatory and redox signaling shifts)
  • G: >3 hr (gene-regulatory adaptation and phenotype-level outcomes)
MAOB, Monoamine oxidase B: Click to Expand ⟱
Source:
Type:
Monoamine oxidase B (MAO-B) is an enzyme involved in the metabolism of monoamines, especially dopamine and phenylethylamine, primarily in the brain. Its activity has been implicated in both Alzheimer's disease (AD) and cancer, but in very different contexts. -Increased MAO-B expression is observed in the brains of aging individuals and even more so in AD patients, particularly in astrocytes.
-High MAO-B activity may accelerate β-amyloid (Aβ) and tau pathology.
-MAO-B inhibitors are potential agents to combat neurodegenerative diseases, including AD and Parkinson’s disease

MAO-B inhibitors have shown anti-cancer effects in preclinical models:
   Inducing apoptosis in tumor cells.
   Sensitizing cells to chemotherapy or radiotherapy.
   Inhibiting tumor angiogenesis and invasion.


Scientific Papers found: Click to Expand⟱
3723- Gb,    Can We Use Ginkgo biloba Extract to Treat Alzheimer’s Disease? Lessons from Preclinical and Clinical Studies
- Review, AD, NA
*memory↑, *antiOx↑, *Casp3↓, *APP↓, *AChE↓, *Aβ↓, *5HT↑, *SOD↓, *MDA↓, *NO↓, *GSH↑, *Bcl-2↑, *BAX↑, *TNF-α↓, *IL1β↑, *iNOS↓, *IL10↓, *p‑tau↓, *ROS↓, *MAOB↓, *cognitive↑, *neuroP↑, *Apoptosis↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   GSH↑, 1,   MDA↓, 1,   ROS↓, 1,   SOD↓, 1,  

Cell Death ⓘ

Apoptosis↓, 1,   BAX↑, 1,   Bcl-2↑, 1,   Casp3↓, 1,   iNOS↓, 1,  

Migration ⓘ

APP↓, 1,  

Angiogenesis & Vasculature ⓘ

NO↓, 1,  

Immune & Inflammatory Signaling ⓘ

IL10↓, 1,   IL1β↑, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission ⓘ

5HT↑, 1,   AChE↓, 1,   p‑tau↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,   MAOB↓, 1,  

Functional Outcomes ⓘ

cognitive↑, 1,   memory↑, 1,   neuroP↑, 1,  
Total Targets: 23

Scientific Paper Hit Count for: MAOB, Monoamine oxidase B
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:89  Target#:1352  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page